NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company
will present at the OctoberINVESTfest Conference on Wednesday, September
28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences
in New York.
A live webcast of the presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60
days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. The company
has pioneered discovery, research and development efforts around analogs
of uroguanylin, a naturally occurring human GI peptide, for the
treatment of functional GI disorders and inflammatory bowel disease.
Synergy discovered, is developing and retains 100% worldwide rights to
its proprietary uroguanylin analog technology platform that includes two
lead product candidates – plecanatide and dolcanatide. Plecanatide is
Synergy’s first uroguanylin analog currently being evaluated for use as
a once-daily tablet for chronic idiopathic constipation and irritable
bowel syndrome with constipation. Dolcanatide is Synergy’s second
uroguanylin analog currently being explored for ulcerative colitis. For
more information, please visit www.synergypharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160923005125/en/
Contacts
Synergy Pharmaceuticals
Gem Hopkins, 212-584-7610
VP, Investor
Relations and Corporate Communications
ghopkins@synergypharma.com
Source: Synergy Pharmaceuticals
Cet article Synergy Pharmaceuticals to Present at OctoberINVESTfest 2016 est apparu en premier sur EEI-BIOTECHFINANCES.